We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

News · September 29, 2020

ESMO 2020: Adjuvant Nivolumab Offers Novel Treatment Advance in Esophageal/Gastroesophageal Junction Cancer

CheckMate 577 has shown improved disease-free survival with nivolumab; it is ongoing, to establish overall survival outcomes

PracticeUpdate Editorial Team


Further Reading